Literature DB >> 35726867

Colonic mucosal microbiota is associated with bowel habit subtype and abdominal pain in patients with irritable bowel syndrome.

Charlene Choo1, Swapna Mahurkar-Joshi2, Tien S Dong3, Adrienne Lenhart3, Venu Lagishetty3, Jonathan P Jacobs3,4, Jennifer S Labus2, Nancee Jaffe3, Emeran A Mayer2, Lin Chang2.   

Abstract

Mucosal microbiota differ significantly from fecal microbiota and may play a different role in the pathophysiology of irritable bowel syndrome (IBS). The aims of this study were to determine if the composition of mucosal microbiota differed between IBS, or IBS bowel habit (BH) subtypes, and healthy controls (HCs). Sigmoid colon mucosal biopsies were obtained from 97 Rome-positive patients with IBS (28% IBS-constipation, 38% IBS-diarrhea, 24% IBS-mixed, and 10% IBS-unsubtyped) and 54 HCs, from which DNA was extracted. 16S rRNA gene sequencing and microbial composition analysis were performed. Group differences in α and β diversity and taxonomic level differences were determined using linear regression while controlling for confounding variables. IBS BH subtype was associated with microbial α diversity (P = 0.0003) with significant differences seen in the mucosal microbiota of IBS-constipation versus IBS-diarrhea (P = 0.046). There were no significant differences in α or β diversity in the mucosal microbiota of IBS versus HCs (P = 0.29 and 0.93, respectively), but metagenomic profiling suggested functional differences. The relative abundance of Prevotella_9 copri within IBS was significantly correlated with increased abdominal pain (r = 0.36, P = 0.0003), which has not been previously reported in IBS. Significant differences in the mucosal microbiota were present within IBS BH subtypes but not between IBS and HCs, supporting the possibility of IBS BH subtype-specific pathogenesis. Increased Prevotella copri may contribute to symptoms in patients with IBS.NEW & NOTEWORTHY Gut mucosal microbiota differs significantly from fecal microbiota in irritable bowel syndrome (IBS) and may play a different role in its pathophysiology. Investigation of colonic mucosal microbiota in the largest cohort of patients with IBS and healthy controls accounting for confounding variables, including diet demonstrated significant differences in mucosal microbiota between IBS bowel habit subtypes but not between IBS and healthy controls. In addition, the study reported gut microbiota is associated with abdominal pain in patients with IBS.

Entities:  

Keywords:  IBS bowel habit subtypes; Prevotella copri; colonic mucosal microbiota; irritable bowel syndrome; microbiota and diet

Mesh:

Substances:

Year:  2022        PMID: 35726867      PMCID: PMC9359639          DOI: 10.1152/ajpgi.00352.2021

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.871


  56 in total

1.  Evidence of the Immune Relevance of Prevotella copri, a Gut Microbe, in Patients With Rheumatoid Arthritis.

Authors:  Annalisa Pianta; Sheila Arvikar; Klemen Strle; Elise E Drouin; Qi Wang; Catherine E Costello; Allen C Steere
Journal:  Arthritis Rheumatol       Date:  2017-04-07       Impact factor: 10.995

2.  Finegoldia magna Isolated from Orthopedic Joint Implant-Associated Infections.

Authors:  Bo Söderquist; Sanna Björklund; Bengt Hellmark; Anders Jensen; Holger Brüggemann
Journal:  J Clin Microbiol       Date:  2017-09-13       Impact factor: 5.948

3.  Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators.

Authors:  T Piche; G Barbara; P Aubert; S Bruley des Varannes; R Dainese; J L Nano; C Cremon; V Stanghellini; R De Giorgio; J P Galmiche; M Neunlist
Journal:  Gut       Date:  2008-09-29       Impact factor: 23.059

4.  integrOmics: an R package to unravel relationships between two omics datasets.

Authors:  Kim-Anh Lê Cao; Ignacio González; Sébastien Déjean
Journal:  Bioinformatics       Date:  2009-08-25       Impact factor: 6.937

5.  Bowel Disorders.

Authors:  Fermín Mearin; Brian E Lacy; Lin Chang; William D Chey; Anthony J Lembo; Magnus Simren; Robin Spiller
Journal:  Gastroenterology       Date:  2016-02-18       Impact factor: 22.682

6.  Prevotella copri in individuals at risk for rheumatoid arthritis.

Authors:  Axel Finckh; Till Strowig; Deshire Alpizar-Rodriguez; Till Robin Lesker; Achim Gronow; Benoît Gilbert; Elena Raemy; Celine Lamacchia; Cem Gabay
Journal:  Ann Rheum Dis       Date:  2019-02-13       Impact factor: 19.103

7.  Oligotyping: Differentiating between closely related microbial taxa using 16S rRNA gene data.

Authors:  A Murat Eren; Loïs Maignien; Woo Jun Sul; Leslie G Murphy; Sharon L Grim; Hilary G Morrison; Mitchell L Sogin
Journal:  Methods Ecol Evol       Date:  2013-12-01       Impact factor: 7.781

Review 8.  Campylobacter ureolyticus: a portrait of the pathogen.

Authors:  Dylan O'Donovan; Gerard D Corcoran; Brigid Lucey; Roy D Sleator
Journal:  Virulence       Date:  2014-04-09       Impact factor: 5.882

9.  The Prevotella copri Complex Comprises Four Distinct Clades Underrepresented in Westernized Populations.

Authors:  Adrian Tett; Kun D Huang; Francesco Asnicar; Hannah Fehlner-Peach; Edoardo Pasolli; Nicolai Karcher; Federica Armanini; Paolo Manghi; Kevin Bonham; Moreno Zolfo; Francesca De Filippis; Cara Magnabosco; Richard Bonneau; John Lusingu; John Amuasi; Karl Reinhard; Thomas Rattei; Fredrik Boulund; Lars Engstrand; Albert Zink; Maria Carmen Collado; Dan R Littman; Daniel Eibach; Danilo Ercolini; Omar Rota-Stabelli; Curtis Huttenhower; Frank Maixner; Nicola Segata
Journal:  Cell Host Microbe       Date:  2019-10-10       Impact factor: 21.023

10.  The Colonic Mucosal MicroRNAs, MicroRNA-219a-5p, and MicroRNA-338-3p Are Downregulated in Irritable Bowel Syndrome and Are Associated With Barrier Function and MAPK Signaling.

Authors:  Swapna Mahurkar-Joshi; Carl Robert Rankin; Elizabeth Jane Videlock; Artin Soroosh; Abhishek Verma; Ariela Khandadash; Dimitrios Iliopoulos; Charalabos Pothoulakis; Emeran A Mayer; Lin Chang
Journal:  Gastroenterology       Date:  2021-02-20       Impact factor: 33.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.